Compare LGIH & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | NNNN |
|---|---|---|
| Founded | 2003 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2013 | 2025 |
| Metric | LGIH | NNNN |
|---|---|---|
| Price | $47.83 | $26.06 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $71.13 | N/A |
| AVG Volume (30 Days) | ★ 330.9K | 26.9K |
| Earning Date | 11-04-2025 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.53 | 0.06 |
| Revenue | ★ $1,788,933,000.00 | $8,185,146.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.77 | N/A |
| P/E Ratio | ★ $10.74 | $534.57 |
| Revenue Growth | N/A | ★ 21.95 |
| 52 Week Low | $39.70 | $5.18 |
| 52 Week High | $104.31 | $55.65 |
| Indicator | LGIH | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 46.07 |
| Support Level | $46.73 | $26.89 |
| Resistance Level | $50.54 | $44.73 |
| Average True Range (ATR) | 2.17 | 5.72 |
| MACD | -0.36 | -0.32 |
| Stochastic Oscillator | 10.77 | 22.84 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company have seven operating segments ( West, Northwest, Central, Midwest, Florida, Southeast and Mid-Atlantic) that it aggregates into five qualifying reportable segment. Majority of the revenue is generated from Central division segment.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.